Swedish Orphan Biovitrum AB (publ) (SOBI.ST)
Develops medicines for rare blood disorders, immune diseases, and specialized conditions worldwide
471.40+0.01%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+78.3%
The outlook
SOBI.ST trades at 471.4 SEK, trading well above both its 50- and 200-day moving averages and near the top of its 52-week range. Analyst consensus leans Buy with an average target sitting about 6% above the current price. The stock carries a notably high trailing P/E of 120.9, reflecting market expectations for future growth.
What’s behind the score
Analyst consensusBuy — 1.9 avg of 12 analysts
Price trendAbove its 50- & 200-day averages
52-week range93% of the way from its 52-week low to high
Price targetAvg target +6% vs current price
Analyst price target
~12-month · 12 analysts498.42average target+5.7% vs now
Now 471.40
Low 350.00High 575.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$164.38B
52-wk high
487.00
52-wk low
261.20
50-day avg
453.22
200-day avg
388.01
Trailing P/E
120.9